Decoy TherapeuticsDCOY
13F holders, Q2 2026 (June 30)4holders
2new positions
2sold out
$7.19avg. 13F price*
At the end of Q2 2026, 4 institutions reported holding Decoy Therapeutics Inc. (DCOY) in their 13F filings, unchanged from Q1 2026. 2 opened new positions and 2 sold out. The largest holders were Vanguard Capital Management LLC ($29K), Tower Research Capital LLC (TRC) ($2K) and UBS Group AG ($180).
- Company
- Decoy Therapeutics Inc.
- CUSIP
- 79400X602
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $29K |
| Exits | 2 | $275 |
All 13F filers, Q1 2026 → Q2 2026: 4,036 shares bought and 1,328 shares sold, net +2,708 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Vanguard Capital Management LLC | 0.00% | New | 4,034 | $29K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -74.9% | 256 | $2K |
| UBS Group AG | 0.00% | Reduce -95.4% | 25 | $180 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 2 | $14 |
"% of holder's portfolio" is DCOY's weight in each manager's 13F, not the share of Decoy Therapeutics Inc. the manager owns.